Principal
Avital Adler has been a Principal at Arkin Bio Ventures since 2025. She is part of the
ABV3 management team, an early-stage fund focused on Seed and Series A
opportunities. Avital leverages her deep scientific expertise and broad investment
experience across private and public markets to identify new investment opportunities
and provide strategic support to portfolio companies.
Before joining Arkin Bio, Avital spent four years at aMoon, where she led scientific and
business diligence for private investments in biotech and tools & diagnostics
companies. She also played a key role in establishing aMoon Edge, the firm’s public
markets platform.
Avital holds a Ph.D. in Neural Computation from the Hebrew University and completed a
postdoctoral fellowship at NYU Medical Center. Her research resulted in 21 peer-
reviewed publications, including in Neuron and Nature Neuroscience.
Let’s get in touch!
